Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Cerno Pharmaceutical
WARNING LETTER
•Cerno Pharmaceutical•November 17, 2017

Cerno Pharmaceutical – FDA Warning Letter, Nov 17, 2017

Record Details

The FDA inspected Cerno Pharmaceuticals, LLC from November 13-17, 2017, identifying significant CGMP and misbranding violations, rendering their drug products adulterated and misbranded.

CGMP violations include: 1. **Failure to withhold components:** The firm used salicylic acid (lot (b)(4)) for Verruguin Wart Remover production before testing and quality unit release, stating they manufactured "at risk." The response to create a deviation report and train staff was deemed inadequate; the FDA requires analytical results for used components and preventative measures. 2. **Inadequate cleaning procedures:** The firm failed to follow its own cleaning procedure (CP-QA-015), performing a minor (dry) cleaning on July 31, 2017, when a major (wet) cleaning was required due to a gap exceeding two months since the last major clean. The response was inadequate for not assessing product quality impact or defining "extended period of time." The FDA requires a revised procedure, training, and enforcement plan. 3. **Failure to maintain adequate equipment records:** The firm lacked proper equipment use logs for the blender and filler, using combined "Room/Equipment Cleaning and Use Logs" that were incomplete and unclear. The provided logs were unacceptable. The FDA requires revised logs with complete information and controls to ensure proper use.

The FDA strongly recommends engaging a qualified CGMP consultant.

Misbranding violations for Verruguin

Company
Cerno Pharmaceutical
Inspection date
November 17, 2017
Product type
Drugs
Office
Dallas District Office
People
  • Monica R. Maxwell (Program Division Director)
  • Lisa Capote
  • Renee Alsobrook
View Company Profile

ID · 7e873b49-4b5a-4fb6-89a9-1c963d5088a5

Violation Codes10
21 CFR 21021 CFR 21121 U.S.C. 351(a)(2)(B)21 CFR 211.84(a)21 CFR 211.67(b)21 CFR 211.182FD&C Act 501(a)(2)(B)FD&C Act 502(c)FD&C Act 502(x)21 U.S.C. 352(c)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cerno Pharmaceutical
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.